NCT02865824

Polypectomy in Patients Taking Dual Antiplatelet Agents

Effects of Antiplatelets Discontinuation in Patients Receiving Polypectomy: Randomized Controlled Trial

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 180 (estimated)
• Sponsor: Incheon St.Mary's Hospital · Academic / Other
• Sex: All
• Age: 20 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Current guidelines recommend discontinuation of antiplatelets (i.e clopidogrel) for 7 days in patients taking DAT (dual antiplatelet therapy) before colonoscopy and polypectomy. The purpose of this study was to examine if a) discontinuation of these drugs reduces bleeding risks during polypectomy and if b) discontinuation of these drugs increases the occurence of thromboembolic events.

Detailed description

Patients taking dual antiplatelets (DAT) and who visited for colonoscopy were eligible for enrollment in this study. On enrollment, patients were randomized to two groups. One group continued DAT and the other group discontinued antiplatelets (i.e. clopidogrel, ticagrelor, prasugrel) for 7 days before colonoscopy. If polyps (≤1 cm) were observed during colonoscopy, they were removed by cold snare polypectomy. The primary aim was to compared the delayed bleeding rates of the two groups.

Conditions

• Colonic Polyps

Interventions

Type	Name	Description
DRUG	Continue thienopyridine	Patients continue dual antiplatelet therapies before colonoscopy. The patients continue taking thienopyridine before colonoscopy
DRUG	Discontinue thienopyridine	Patients who are taking dual antiplatelet therapies stop thienopyridine one week before they undergo colonoscopy

Timeline

• Start date: 2016-01-01
• Primary completion: 2018-12-01
• Completion: 2019-03-01
• First posted: 2016-08-15
• Last updated: 2016-08-17

Locations

1 site across 1 country: South Korea